These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29285389)

  • 1. Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control?
    Tamai T; Kumagai K; Sakae H; Onishi H; Tabu K; Tabu E; Muromachi K; Saishoji A; Oda K; Mawatari S; Moriuchi A; Sakurai K; Ido A
    Mol Clin Oncol; 2017 Dec; 7(6):1135-1141. PubMed ID: 29285389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
    Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
    Yao X; Yan D; Zeng H; Liu D; Li H
    J Surg Oncol; 2016 May; 113(6):672-7. PubMed ID: 26989044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization (TACE) Combined with Sorafenib
    Ren B; Wang W; Shen J; Li W; Ni C; Zhu X
    J Cancer; 2019; 10(5):1189-1196. PubMed ID: 30854128
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization.
    Fan W; Zhu B; Zheng X; Yue S; Lu M; Fan H; Qiao L; Li F; Yuan G; Wu Y; Zou X; Wang H; Xue M; Li J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1873-1882. PubMed ID: 35788728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.
    Dai Y; Jiang H; Jiang H; Zhao S; Zeng X; Sun R; Zheng R
    Transl Oncol; 2021 Dec; 14(12):101238. PubMed ID: 34628285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies.
    Li H; Li S; Geng J; Zhao S; Tan K; Yang Z; Feng D; Liu L
    Ann Transl Med; 2020 Apr; 8(8):540. PubMed ID: 32411763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study.
    Peng TR; Wu TW; Wu CC; Chang SY; Chan CY; Hsu CS
    Tzu Chi Med J; 2022; 34(2):219-225. PubMed ID: 35465280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.
    Patidar Y; Chandel K; Condati NK; Srinivasan SV; Mukund A; Sarin SK
    J Clin Exp Hepatol; 2022; 12(3):745-754. PubMed ID: 35677519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
    Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
    Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
    J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma.
    Wu Y; Qi H; Cao F; Shen L; Chen S; Xie L; Huang T; Song Z; Zhou D; Fan W
    Front Pharmacol; 2020; 11():1130. PubMed ID: 32903854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study.
    Wu J; Li A; Yang J; Lu Y; Li J
    Onco Targets Ther; 2017; 10():2761-2768. PubMed ID: 28603426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
    Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
    Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.